FDA CBER Finalizes Compliance Policy on Blood Donation Suitability and Source Plasma Quarantine Hold Requirements

CBER has finalized its compliance policy on donation suitability, donor eligibility, and Source Plasma quarantine holds, giving blood establishments and plasma collection facilities a clearer enforcement boundary under three specific 21 CFR provisions. The guidance, issued under docket FDA-2022-D-0588, defines the conditions under which FDA does not intend to take regulatory action for non-compliance with those requirements.

The three regulatory provisions in scope are 21 CFR 630.30 (donation suitability), 21 CFR 630.10(c)(2) (donor eligibility), and 21 CFR 640.69(f) (quarantine hold for Source Plasma). For QA directors and regulatory affairs leads at plasma and biologics facilities, the practical read is that FDA is codifying enforcement discretion rather than relaxing the underlying standards. Facilities remain obligated to maintain compliant SOPs and documentation; the guidance narrows the circumstances where deviation triggers formal regulatory action.

This final guidance supersedes the April 2020 document, "Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency," which had provided temporary operational flexibility during the public health emergency. It also finalizes the May 2022 draft of the same title, closing a four-year rulemaking cycle. Facilities that aligned internal procedures to the 2020 emergency guidance or the 2022 draft should conduct a gap assessment against the finalized text to confirm continued alignment.

For plant heads managing Source Plasma collection, the quarantine hold provision under 21 CFR 640.69(f) carries direct operational weight. Quarantine hold procedures intersect with inventory management, release timelines, and downstream biologics manufacturing schedules. Any deviation from hold requirements that falls outside the enforcement discretion boundary described in this guidance remains subject to standard CBER inspection findings and potential regulatory action.

The guidance was issued by CBER's Office of Communication, Outreach and Development and is available for public comment at any time under 21 CFR 10.115(g)(5), with submissions directed to docket FDA-2022-D-0588. Written comments should be mailed to FDA's Dockets Management office in Rockville, Maryland.

Facilities should prioritize a formal review of donor eligibility documentation practices and Source Plasma quarantine hold records against the finalized provisions before the next scheduled CBER inspection cycle.

Source: FDA Center for Biologics Evaluation and Research via What's New: Vaccines, Blood & Biologics RSS Feed, October 14, 2026.